Issues in blinded sample size re-estimation

The utility of blinded sample size re-estimation for clinical trials depends on the ability to estimate variability without providing information about the true treatment difference, and on some reasonable assurance that the method is not likely to cause the sample size to be increased when the treatment effect is better than anticipated. We show that violations of these properties are unlikely to occur in practice.